Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 12(5)2020 05 14.
Article in English | MEDLINE | ID: mdl-32422922

ABSTRACT

The non-structural protein NS1 of influenza A viruses is considered to be the major antagonist of the interferon system and antiviral defenses of the cell. It could therefore represent a suitable target for novel antiviral strategies. As a first step towards the identification of small compounds targeting NS1, we here investigated the druggable potential of its RNA-binding domain since this domain is essential to the biological activities of NS1. We explored the flexibility of the full-length protein by running molecular dynamics simulations on one of its published crystal structures. While the RNA-binding domain structure was remarkably stable along the simulations, we identified a flexible site at the two extremities of the "groove" that is delimited by the antiparallel α-helices that make up its RNA-binding interface. This groove region is able to form potential binding pockets, which, in 60% of the conformations, meet the druggability criteria. We characterized these pockets and identified the residues that contribute to their druggability. All the residues involved in the druggable pockets are essential at the same time to the stability of the RNA-binding domain and to the biological activities of NS1. They are also strictly conserved across the large sequence diversity of NS1, emphasizing the robustness of this search towards the identification of broadly active NS1-targeting compounds.


Subject(s)
Influenza A virus/metabolism , Influenza, Human/virology , Viral Nonstructural Proteins/chemistry , Binding Sites , Crystallography, X-Ray , Humans , Influenza A virus/chemistry , Influenza A virus/genetics , Molecular Dynamics Simulation , RNA, Viral/chemistry , RNA, Viral/genetics , RNA, Viral/metabolism , RNA-Binding Motifs , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/metabolism
2.
Mol Inform ; 36(9)2017 09.
Article in English | MEDLINE | ID: mdl-28452177

ABSTRACT

Small molecules interact with their protein target on surface cavities known as binding pockets. Pocket-based approaches are very useful in all of the phases of drug design. Their first step is estimating the binding pocket based on protein structure. The available pocket-estimation methods produce different pockets for the same target. The aim of this work is to investigate the effects of different pocket-estimation methods on the results of pocket-based approaches. We focused on the effect of three pocket-estimation methods on a pocket-ligand (PL) classification. This pocket-based approach is useful for understanding the correspondence between the pocket and ligand spaces and to develop pharmacological profiling models. We found pocket-estimation methods yield different binding pockets in terms of boundaries and properties. These differences are responsible for the variation in the PL classification results that can have an impact on the detected correspondence between pocket and ligand profiles. Thus, we highlighted the importance of the pocket-estimation method choice in pocket-based approaches.


Subject(s)
Molecular Docking Simulation/methods , Sequence Analysis, Protein/methods , Animals , Binding Sites , Humans , Ligands , Protein Binding
3.
Drug Discov Today ; 22(2): 404-415, 2017 02.
Article in English | MEDLINE | ID: mdl-27939283

ABSTRACT

During the preliminary stage of a drug discovery project, the lack of druggability information and poor target selection are the main causes of frequent failures. Elaborating on accurate computational druggability prediction methods is a requirement for prioritizing target selection, designing new drugs and avoiding side effects. In this review, we describe a survey of recently reported druggability prediction methods mainly based on networks, statistical pocket druggability predictions and virtual screening. An application for a frequent mutation of p53 tumor suppressor is presented, illustrating the complementarity of druggability prediction approaches, the remaining challenges and potential new drug development perspectives.


Subject(s)
Drug Discovery , Models, Theoretical , Binding Sites , DNA/metabolism , Humans , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...